TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells - PubMed
- ️Tue May 08 2007
TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells
Andreas Zirlik et al. Arterioscler Thromb Vasc Biol. 2007 May.
Abstract
Objective: Several lines of evidence implicate CD40 ligand (CD40L, CD154) as a mediator and marker of atherosclerosis. This study investigated the involvement of tumor necrosis factor receptor-associated factors (TRAFs) in CD40 signaling in endothelial cells (ECs) and their expression in atheromata and cells involved in atherogenesis.
Methods and results: CD40L enhanced the basal expression of TRAF-1, -2, -3, and 6, but not TRAF-5 in ECs. TRAFs associated with CD40 on ligation by CD40L. Study of ECs from TRAF-1, -2, and -5-deficient mice demonstrated functional involvement of TRAFs in proinflammatory CD40 signaling. Whereas TRAF-1 deficiency enhanced CD40L-induced IL-6 and MCP-1 expression, TRAF-2 and TRAF-5 deficiency inhibited CD40L-inducible IL-6 but not MCP-1 expression. Gene silencing in human ECs further delineated functions of TRAFs in CD40 signaling. TRAF-3 silencing in ECs showed increased CD40L-induced IL-6, MCP-1, and IL-8 expression, whereas TRAF-6 silencing increased selectively CD40L-induced MCP-1 expression. Enhanced TRAF levels in atherosclerotic lesions further supports involvement of members of this family of signaling molecules in arterial disease.
Conclusions: These results implicate endothelial TRAF-1, -2, -3, -5, and -6 in CD40 signaling in atherogenesis, identifying these molecules as potential targets for selective therapeutic intervention.
Similar articles
-
Pullen SS, Labadia ME, Ingraham RH, McWhirter SM, Everdeen DS, Alber T, Crute JJ, Kehry MR. Pullen SS, et al. Biochemistry. 1999 Aug 3;38(31):10168-77. doi: 10.1021/bi9909905. Biochemistry. 1999. PMID: 10433725
-
Lutgens E, Lievens D, Beckers L, Wijnands E, Soehnlein O, Zernecke A, Seijkens T, Engel D, Cleutjens J, Keller AM, Naik SH, Boon L, Oufella HA, Mallat Z, Ahonen CL, Noelle RJ, de Winther MP, Daemen MJ, Biessen EA, Weber C. Lutgens E, et al. J Exp Med. 2010 Feb 15;207(2):391-404. doi: 10.1084/jem.20091293. Epub 2010 Jan 25. J Exp Med. 2010. PMID: 20100871 Free PMC article.
-
Xia M, Ling W, Zhu H, Wang Q, Ma J, Hou M, Tang Z, Li L, Ye Q. Xia M, et al. Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):519-24. doi: 10.1161/01.ATV.0000254672.04573.2d. Epub 2006 Dec 7. Arterioscler Thromb Vasc Biol. 2007. PMID: 17158355
-
Tumor necrosis factor receptor-associated factors (TRAFs).
Bradley JR, Pober JS. Bradley JR, et al. Oncogene. 2001 Oct 1;20(44):6482-91. doi: 10.1038/sj.onc.1204788. Oncogene. 2001. PMID: 11607847 Review.
-
The multi-functionality of CD40L and its receptor CD40 in atherosclerosis.
Lievens D, Eijgelaar WJ, Biessen EA, Daemen MJ, Lutgens E. Lievens D, et al. Thromb Haemost. 2009 Aug;102(2):206-14. doi: 10.1160/TH09-01-0029. Thromb Haemost. 2009. PMID: 19652870 Review.
Cited by
-
Structural feature of TRAFs, their related human diseases and therapeutic intervention.
Park HH. Park HH. Arch Pharm Res. 2021 May;44(5):475-486. doi: 10.1007/s12272-021-01330-w. Epub 2021 May 10. Arch Pharm Res. 2021. PMID: 33970438 Review.
-
Genetically driven target tissue overexpression of CD40: a novel mechanism in autoimmune disease.
Huber AK, Finkelman FD, Li CW, Concepcion E, Smith E, Jacobson E, Latif R, Keddache M, Zhang W, Tomer Y. Huber AK, et al. J Immunol. 2012 Sep 15;189(6):3043-53. doi: 10.4049/jimmunol.1200311. Epub 2012 Aug 10. J Immunol. 2012. PMID: 22888137 Free PMC article.
-
Donners MM, Beckers L, Lievens D, Munnix I, Heemskerk J, Janssen BJ, Wijnands E, Cleutjens J, Zernecke A, Weber C, Ahonen CL, Benbow U, Newby AC, Noelle RJ, Daemen MJ, Lutgens E. Donners MM, et al. Blood. 2008 May 1;111(9):4596-604. doi: 10.1182/blood-2007-05-088906. Epub 2008 Jan 14. Blood. 2008. PMID: 18195092 Free PMC article.
-
The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease.
Bosmans LA, Bosch L, Kusters PJH, Lutgens E, Seijkens TTP. Bosmans LA, et al. J Cardiovasc Transl Res. 2021 Feb;14(1):13-22. doi: 10.1007/s12265-020-09994-3. Epub 2020 Mar 28. J Cardiovasc Transl Res. 2021. PMID: 32222950 Free PMC article. Review.
-
Tiboldi A, Hunyadi-Gulyas E, Wohlrab P, Schmid JA, Markstaller K, Klein KU, Tretter V. Tiboldi A, et al. Antioxidants (Basel). 2022 Nov 28;11(12):2349. doi: 10.3390/antiox11122349. Antioxidants (Basel). 2022. PMID: 36552557 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous